Display options
Cite
Carreño JM, McDonald JU, Hurst T, et al. Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines (Basel). 2020;8(4)doi: 10.3390/vaccines8040666.
Carreño, J. M., McDonald, J. U., Hurst, T., Rigsby, P., Atkinson, E., Charles, L., Nachbagauer, R., Behzadi, M. A., Strohmeier, S., Coughlan, L., Aydillo, T., Brandenburg, B., García-Sastre, A., Kaszas, K., Levine, M. Z., Manenti, A., McDermott, A. B., Montomoli, E., Muchene, L., Narpala, S. R., Perera, R. A. P. M., Salisch, N. C., Valkenburg, S. A., Zhou, F., Engelhardt, O. G., & Krammer, F. (2020). Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines, 8(4), . https://doi.org/10.3390/vaccines8040666
Carreño, Juan Manuel, et al. "Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies." Vaccines vol. 8,4 (2020). doi: https://doi.org/10.3390/vaccines8040666
Carreño JM, McDonald JU, Hurst T, Rigsby P, Atkinson E, Charles L, Nachbagauer R, Behzadi MA, Strohmeier S, Coughlan L, Aydillo T, Brandenburg B, García-Sastre A, Kaszas K, Levine MZ, Manenti A, McDermott AB, Montomoli E, Muchene L, Narpala SR, Perera RAPM, Salisch NC, Valkenburg SA, Zhou F, Engelhardt OG, Krammer F. Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines (Basel). 2020 Nov 09;8(4). doi: 10.3390/vaccines8040666. PMID: 33182279; PMCID: PMC7712758.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2020 Nov 09;8(4). doi: 10.3390/vaccines8040666.

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.

Vaccines

Juan Manuel Carreño, Jacqueline U McDonald, Tara Hurst, Peter Rigsby, Eleanor Atkinson, Lethia Charles, Raffael Nachbagauer, Mohammad Amin Behzadi, Shirin Strohmeier, Lynda Coughlan, Teresa Aydillo, Boerries Brandenburg, Adolfo García-Sastre, Krisztian Kaszas, Min Z Levine, Alessandro Manenti, Adrian B McDermott, Emanuele Montomoli, Leacky Muchene, Sandeep R Narpala, Ranawaka A P M Perera, Nadine C Salisch, Sophie A Valkenburg, Fan Zhou, Othmar G Engelhardt, Florian Krammer

Affiliations

  1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.
  2. Division of Virology, National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar EN6 3QG, UK.
  3. Division of Analytical and Biological Sciences, National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar EN6 3QG, UK.
  4. Department of Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
  5. Global Health and Emerging Pathogens Institute, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.
  6. Janssen Vaccines & Prevention BV, 2333 CP Leiden, The Netherlands.
  7. Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.
  8. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.
  9. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  10. VisMederi Research srl, 53100 Siena, Italy.
  11. Vaccine Immunology Program (VIP), Vaccine Research Center (VRC), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  12. Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  13. School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  14. Influenza Center, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
  15. K.G. Jebsen Center for influenza vaccines, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.

PMID: 33182279 PMCID: PMC7712758 DOI: 10.3390/vaccines8040666

Abstract

The stalk domain of the hemagglutinin has been identified as a target for induction of protective antibody responses due to its high degree of conservation among numerous influenza subtypes and strains. However, current assays to measure stalk-based immunity are not standardized. Hence, harmonization of assay readouts would help to compare experiments conducted in different laboratories and increase confidence in results. Here, serum samples from healthy individuals (

Keywords: hemagglutinin; influenza vaccine; serology; stalk; standardization

References

  1. J Virol. 2014 Dec;88(23):13580-92 - PubMed
  2. Vaccine. 2017 May 25;35(23):3082-3088 - PubMed
  3. Science. 2012 Sep 14;337(6100):1343-8 - PubMed
  4. J Exp Med. 1994 May 1;179(5):1719-24 - PubMed
  5. J Virol. 2015 Apr;89(7):3610-8 - PubMed
  6. Clin Infect Dis. 2020 Aug 14;71(4):1072-1079 - PubMed
  7. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4800-4 - PubMed
  8. Vaccine. 2020 Feb 18;38(8):1953-1961 - PubMed
  9. mBio. 2017 Sep 19;8(5): - PubMed
  10. Science. 2011 Aug 12;333(6044):850-6 - PubMed
  11. Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8 - PubMed
  12. J Virol. 2019 Apr 3;93(8): - PubMed
  13. Nat Rev Immunol. 2019 Jun;19(6):383-397 - PubMed
  14. J Virol. 2014 Nov;88(22):13260-8 - PubMed
  15. J Infect Dis. 1998 Jun;177(6):1710-4 - PubMed
  16. PLoS One. 2013 Dec 11;8(12):e80034 - PubMed
  17. J Infect Dis. 2018 Jul 2;218(3):347-354 - PubMed
  18. Vaccine. 2018 Nov 29;36(50):7641-7649 - PubMed
  19. Sci Rep. 2018 Jul 11;8(1):10432 - PubMed
  20. Sci Transl Med. 2013 Aug 14;5(198):198ra107 - PubMed
  21. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17040-5 - PubMed
  22. NPJ Vaccines. 2019 Dec 6;4:51 - PubMed
  23. Science. 2009 Apr 10;324(5924):246-51 - PubMed
  24. Lancet Infect Dis. 2020 Jan;20(1):80-91 - PubMed
  25. Nat Med. 2014 Feb;20(2):143-51 - PubMed
  26. mBio. 2018 Jan 23;9(1): - PubMed
  27. Nat Med. 2019 Jun;25(6):962-967 - PubMed
  28. mBio. 2016 Jan 19;7(1):e01996-15 - PubMed
  29. Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8 - PubMed
  30. Emerg Infect Dis. 2009 Aug;15(8):1252-9 - PubMed
  31. Nat Immunol. 2017 Apr;18(4):464-473 - PubMed
  32. Immunohorizons. 2019 Apr 1;3(4):133-148 - PubMed
  33. Nat Med. 2015 Sep;21(9):1065-70 - PubMed
  34. PLoS One. 2018 Apr 4;13(4):e0194830 - PubMed
  35. J Virol. 1993 May;67(5):2552-8 - PubMed
  36. Curr Opin Virol. 2012 Apr;2(2):134-41 - PubMed
  37. J Virol. 2019 Mar 5;93(6): - PubMed
  38. PLoS One. 2015 Dec 30;10(12):e0146021 - PubMed
  39. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20248-53 - PubMed
  40. NPJ Vaccines. 2017 Dec 15;2:35 - PubMed
  41. Science. 2015 Sep 18;349(6254):1301-6 - PubMed
  42. Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7): - PubMed
  43. J Infect Dis. 2019 Apr 8;219(Suppl_1):S62-S67 - PubMed
  44. J Virol. 2011 Dec;85(24):13463-7 - PubMed
  45. Vaccine. 2012 Jun 8;30(27):4113-22 - PubMed

Publication Types

Grant support